| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f47c750954e13a1ed0be96c1bf1c51c7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate |
2008-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b033cbdeccc620fcedae2c48c5f0cf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_043fd3aa82504cb35e5665f05392947d |
| publicationDate |
2009-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009030081-A1 |
| titleOfInvention |
Use of lr-90 and lr-102 to overcome insulin resistance |
| abstract |
The present invention provides methods for ameliorating, overcoming, or inhibiting insulin resistance in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of LR-90 and LR-102, or a pharmaceutically acceptable salt or derivative thereof. Methods of treating type 2 diabetes and diabetic nephropathy, or preventing or slowing their development are also encompassed by the invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020190984-A1 |
| priorityDate |
2007-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |